FindTrial
Sign In

Effect of Homoeopathic medicine Oophorinum along with lifestyle changes in managing Polycystic Ovarian Syndrome.

Efficacy of Oophorinum with lifestyle modification in the management of Polycystic ovarian syndrome- A Sequential, Quasi-experimental study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110755
Enrollment
40
Registered
2026-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Homoeopathic Medicine- Oophorinum 30 C and Oophorinum 200 C: Participants will receive the homoeopathic medicine Oophorinum. Potency: Oophorinum 30C Dose: 6 globules. Globule size-30 Mo

Sponsors

Dr Harshita Kulshrestha
Lead Sponsor
Homoeopathy University Jaipur
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Females in the age group of 15 to 45 years. Old and New cases of Polycystic ovarian syndrome (PCOS) diagnosed based on Rotterdam criteria. Patients willing to participate in the study, who give consent. Patients of all religions and different socio-economic status. Patients who are visiting the OPD for regular follow-ups.

Exclusion criteria

Exclusion criteria: Patients who have undergone Ovarian surgery. Patients with uncontrolled Blood sugar levels; HbA1C more than 8%. Known cases of chronic kidney or liver disease. Patients with BMI of more than 35. Patients suffering from other Endocrine or metabolic disorders, Androgen-secreting tumors (ovarian or adrenal), Hyperprolactinemia. Patients with Thyroid disorders (Hypo- or hyperthyroidism). Patients who are Pregnant or lactating. Patients who cannot express their symptoms. Patients taking any other mode of treatment. Use of medications affecting hormones or metabolism- Hormonal contraceptives (usually within the last 3 months), Anti-androgens (e.g., spironolactone, flutamide), Insulin-sensitizing drugs (e.g., metformin, thiazolidinediones), Glucocorticoids, Fertility drugs or ovulation-induction drugs.

Design outcomes

Primary

MeasureTime frame
Menstrual irregularity (Menstrual History Chart) and Quality of life (PCOSQ Scale)Timepoint: At 3 months and 6 months—

Secondary

MeasureTime frame
Ultrasonography- Lower abdomenTimepoint: At 3 months and 6 months;Body-mass indexTimepoint: At 3 months and 6 months;HirsutismTimepoint: At 3 months and 6 months;AcneTimepoint: At 3 months and 6 months;If present, DyssmenorrhoeaTimepoint: At 3 months and 6 months—

Countries

India

Contacts

Public ContactDr HARSHITA KULSHRESTHA

Homoeopathy University, Jaipur

soniatuteja860@gmail.com9530454132

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026